These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22506441)

  • 21. [Galactorrhoea and the use of selective serotonin reuptake inhibitors].
    Wessels-van Middendorp AM; Timmerman L
    Tijdschr Psychiatr; 2006; 48(3):229-34. PubMed ID: 16956087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prolactin response to d-fenfluramine in obsessive-compulsive patients, and outcome of fluvoxamine treatment.
    Monteleone P; Catapano F; Di Martino S; Ferraro C; Maj M
    Br J Psychiatry; 1997 Jun; 170():554-7. PubMed ID: 9330023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case report of risperidone-induced obsessive-compulsive symptoms.
    Alzaid K; Jones BD
    J Clin Psychopharmacol; 1997 Feb; 17(1):58-9. PubMed ID: 9004062
    [No Abstract]   [Full Text] [Related]  

  • 24. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Galactorrhea and gynecomastia in a hypothyroid male being treated with risperidone.
    Mabini R; Wergowske G; Baker FM
    Psychiatr Serv; 2000 Aug; 51(8):983-5. PubMed ID: 10913449
    [No Abstract]   [Full Text] [Related]  

  • 26. Sertraline in the treatment of clozapine-induced obsessive-compulsive behavior.
    Rahman MS; Grace JJ; Pato MT; Priest B
    Am J Psychiatry; 1998 Nov; 155(11):1629-30. PubMed ID: 9812137
    [No Abstract]   [Full Text] [Related]  

  • 27. Hyperpigmentation with amisulpride.
    Mendhekar DN
    Aust N Z J Psychiatry; 2009 Jan; 43(1):88. PubMed ID: 19086350
    [No Abstract]   [Full Text] [Related]  

  • 28. Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial.
    Shalbafan M; Malekpour F; Tadayon Najafabadi B; Ghamari K; Dastgheib SA; Mowla A; Shirazi E; Eftekhar Ardebili M; Ghazizadeh-Hashemi M; Akhondzadeh S
    J Psychopharmacol; 2019 Nov; 33(11):1407-1414. PubMed ID: 31575326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. "Dopamine-dependent" side effects of selective serotonin reuptake inhibitors: a clinical review.
    Damsa C; Bumb A; Bianchi-Demicheli F; Vidailhet P; Sterck R; Andreoli A; Beyenburg S
    J Clin Psychiatry; 2004 Aug; 65(8):1064-8. PubMed ID: 15323590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Obsessive-compulsive symptoms with risperidone.
    Mahendran R
    J Clin Psychiatry; 1999 Apr; 60(4):261-3. PubMed ID: 10221290
    [No Abstract]   [Full Text] [Related]  

  • 31. Risperidone-induced galactorrhoea: a case series.
    Gupta SC; Jagadheesan K; Basu S; Paul SE
    Can J Psychiatry; 2003 Mar; 48(2):130-1. PubMed ID: 12655919
    [No Abstract]   [Full Text] [Related]  

  • 32. Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
    Andrade C
    J Clin Psychiatry; 2012 Nov; 73(11):e1362-4. PubMed ID: 23218164
    [No Abstract]   [Full Text] [Related]  

  • 33. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
    Kinon BJ; Ahl J; Liu-Seifert H; Maguire GA
    Psychoneuroendocrinology; 2006 Jun; 31(5):577-88. PubMed ID: 16488084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.
    Goodman WK; Kozak MJ; Liebowitz M; White KL
    Int Clin Psychopharmacol; 1996 Mar; 11(1):21-9. PubMed ID: 8732310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
    Heidari M; Zarei M; Hosseini SM; Taghvaei R; Maleki H; Tabrizi M; Fallah J; Akhondzadeh S
    Int Clin Psychopharmacol; 2014 Nov; 29(6):344-50. PubMed ID: 24850229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurotoxic syndrome associated with risperidone and fluvoxamine.
    Reeves RR; Mack JE; Beddingfield JJ
    Ann Pharmacother; 2002 Mar; 36(3):440-3. PubMed ID: 11895057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
    Saxena S; Wang D; Bystritsky A; Baxter LR
    J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The treatment of OCD].
    Sumitani S; Ohmori T
    Ryoikibetsu Shokogun Shirizu; 2003; (38):442-5. PubMed ID: 12877022
    [No Abstract]   [Full Text] [Related]  

  • 39. Sertraline-induced galactorrhea: case report and review of cases reported with other SSRIs.
    Nebhinani N
    Gen Hosp Psychiatry; 2013; 35(5):576.e3-5. PubMed ID: 23260337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Response to risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
    Berigan TR; Harazin JS
    J Clin Psychiatry; 1996 Dec; 57(12):594-5. PubMed ID: 9010126
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.